Table 3.
Proportion of clinical sequelae in the first 30 days comparing SARS-CoV-2-diagnosed individuals who received MAb therapy versus standard of care, OptumLabs’ deidentified administrative claims
| Cohort number of sequelae |
MAb therapy group Events/total (%) |
SOC comparison group Events/total (%) |
Comparison of 90-day sequelae prevalence rates Diff % (95% CI) |
P value for χ2 test | P value for interaction in ANOVA test |
| Overall | |||||
| No sequelae | 3502/3798 (92.2) | 3480/3798 (91.6) | 0.6 (−0.6, 1.8) | 0.50 | |
| 1–2 sequelae | 283/3798 (7.5) | 300/3798 (7.9) | −0.4 (−1.6, 0.7) | ||
| ≥3 sequelae | 13/3798 (0.3) | 18/3798 (0.5) | −0.1 (−0.4, 0.2) | ||
| Age (years) | |||||
| ≥65 | 0.49 | ||||
| No sequelae | 1,246/1,380 (90.3) | 1,228/1,380 (89.0) | 1.3 (−1.0, 3.6) | 0.35 | |
| 1–2 sequelae | 127/1,380 (9.2) | 140/1,380 (10.1) | −0.9 (−3.1, 1.3) | ||
| ≥3 sequelae | 7/1,380 (0.5) | 12/1,380 (0.9) | −0.4 (−1.0, 0.3) | ||
| <65 | |||||
| No sequelae | 2256/2418 (93.3) | 2252/2418 (93.1) | 0.2 (−1.3, 1.6) | 0.97 | |
| 1–2 sequelae | 156/2418 (6.5) | 160/2418 (6.6) | −0.2 (−1.6, 1.2) | ||
| ≥3 sequelae | 6/2418 (0.2) | 6/2418 (0.2) | 0.0 (−0.3, 0.3) | ||
| Gender | |||||
| Male | 0.59 | ||||
| No sequelae | 1763/1911 (92.3) | 1709/1871 (91.3) | 0.9 (−0.8, 2.7) | 0.34 | |
| 1–2 sequelae | 142/1911 (7.4) | 151/1871 (8.1) | −0.6 (−2.3, 1.1) | ||
| ≥3 sequelae | 6/1911 (0.3) | 11/1871 (0.6) | −0.3 (−0.7, 0.2) | ||
| Female | |||||
| No sequelae | 1739/1887 (92.2) | 1771/1927 (91.9) | 0.3 (−1.5, 2.0) | 0.95 | |
| 1–2 sequelae | 141/1887 (7.5) | 149/1927 (7.7) | −0.3 (−1.9, 1.4) | ||
| ≥3 sequelae | 7/1887 (0.4) | 7/1927 (0.4) | 0.0 (−0.4, 0.4) | ||
ANOVA, analysis of variance; MAb, monoclonal antibody; SOC, standard of care.